Personal Genome Diagnostics provides kitted, end‑to‑end comprehensive genomic profiling solutions for solid tumor tissue and liquid biopsy samples that can be run in‑house. Their FDA‑cleared and CE‑IVD marked elio kits cover 500+ cancer‑related genes and include an automated bioinformatics pipeline that delivers clinical‑grade reports in as few as five days, enabling laboratories to obtain rapid, reliable genomic insights and support personalized cancer treatment decisions.
Funding
$103M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
9OCHFounders
Product
Problem
Many cancer patients lack timely access to comprehensive genomic profiling because existing tests require centralized labs, complex workflows, and lengthy turnaround times, limiting personalized treatment decisions.
Solution
Personal Genome Diagnostics (PGDx) offers kitted, end‑to‑end comprehensive genomic profiling (CGP) solutions for both solid tumor tissue and liquid biopsy samples that can be run in‑house. Their FDA‑cleared, CE‑IVD marked elio tissue complete kit and research‑use liquid biopsy kits cover 500+ cancer‑related genes and detect SNVs, indels, amplifications, translocations, tumor mutation burden, microsatellite instability, and other biomarkers. Integrated proprietary bioinformatics automates data processing and generates clinical‑grade reports without manual interpretation, delivering results in as few as five days. The turnkey workflow enables laboratories to retain specimen and data control, achieve rapid turnaround, and meet reimbursement pathways through verification rather than full validation. By distributing kits globally, PGDx democratizes access to precision oncology testing for clinicians and researchers.
Target Audience
Primary customers are clinical laboratories and pathology groups that perform in‑house oncology testing, as well as academic and pharmaceutical research teams conducting biomarker discovery and clinical trial genomics.
Features
- FDA‑cleared elio tissue complete kit with 500+ gene panel, including SNVs, indels, TMB, MSI, amplifications and translocations
- CE‑IVD marked version for use in Europe, enabling global deployment
- Liquid biopsy elio plasma complete assay covering 500+ genes, low DNA input (≈25 ng) and high coverage (25,000×)
- Automated, proprietary bioinformatics pipeline using machine‑learning curated training data for >99% sensitivity and specificity
- Sample‑to‑answer workflow with 5‑day turnaround from nucleic acid extraction to variant report
- Turnkey kit design allows verification instead of full validation, simplifying regulatory and reimbursement pathways
- Professional services for middleware integration, custom reporting, and implementation support